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Abstract
Objectives: The aim of this study was to compare among PCNAand Ki-67 as the most reliable immunohisto-
chemical marker for evaluating cell proliferation in ameloblastic tumors. 
Study Design: Observational, retrospective, and descriptive study of a large series of ameloblastic tumors, com-
posed of 161 ameloblastomas and four ameloblastic carcinomas, to determine and compare PCNA and Ki-67 
expression using immunohistochemistry techniques. 
Results: When analyzing Ki-67 positivity, the desmoplastic ameloblastoma demonstrated a significantly lower 
proliferation rate (1.9%) compared with the solid/multicystic and unicystic ameloblastomas and ameloblastic car-
cinomas (p<0.05), whereas the ameloblastic carcinomas displayed a significantly higher rate compared with all of 
the other ameloblastomas (48.7%) (p<0.05). When analyzing cell proliferation with PCNA, we found significant 
differences only between the ameloblastic carcinomas (93.3%) and the desmoplastic ameloblastomas (p<0.05). 
When differences between the immunopositivity for PCNA and Ki-67 were compared, the percentages were 
higher for PCNA in all types of ameloblastomas and ameloblastic carcinomas. In all cases, the percentages were 
greater than 80%, whereas the immunopositivity for Ki-67 was significantly lower; for example, the ameloblastic 
carcinoma expressed the highest positivity and only reached 48.7%, compared to 93.3% when we used PCNA.
Conclusions: In the present study, when we used the proliferation cell marker Ki-67, the percentages of positiv-
ity were more specific and varied among the different types of ameloblastomas, suggesting that Ki-67 is a more 
specific marker for the proliferation of ameloblastic tumor cells.
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Introduction
Cell proliferation is a biological process that is essential 
to all living organisms due to its role in the growth and 
maintenance of tissue homeostasis (1). The control of this 
important process is completely dysregulated in some 
types of neoplasias (2,3), and the assessment of cell pro-
liferation activity in tumors has become a common tool 
used by histopathologists to provide useful information 
for assessing diagnosis, clinical behavior, and therapy.
The cell cycle consists of a series of phases, during 
which there are changes that lead to cell division. Cell 
regulatory genes modulate the cell cycle in a highly so-
phisticated fashion via a number of proteins (4).
Proliferation markers refers to specific proteins or other 
factors whose presence in actively growing and divid-
ing cells serves as an indicator for such cells. 
Today, the most common method for determining pro-
liferative activity is the use of immunohistochemical 
techniques, which are increasingly being applied in 
routine pathology.
The Ki-67 antigen (Ki-67) is a classic marker of cellular 
proliferation that has been widely applied in the diag-
nostic, research and drug-discovery fields. The Ki-67 
antigen was originally defined by the monoclonal an-
tibody Ki-67, with the name derived from the city of 
origin (Kiel) and the number of the original clone in 
the 96-well plate (5). The monoclonal antibody Ki67 
was first described in 1983 by Johannes Gerdes and col-
leagues, who suggested that it might be used as a marker 
for proliferating cells (5).
The Ki-67 antigen is preferentially expressed during the 
late G1, S, G2 and M phase of the cell cycle, whereas 
resting, non-cycling cells (G0 phase) lack Ki-67 ex-
pression. Because of its absence in quiescent cells (G0 
phase), this protein developed into a widely used tu-
mor marker in the fields of research and pathology. The 
standard antibody for the detection of Ki-67 is MIB-1. 
The fraction of MIB-1-positive tumor cells (the MIB-1/
Ki-67 labeling index) is often correlated with the clini-
cal course of cancer; Ki-67is of prognostic value for 
many types of malignant tumors (6).
Proliferating Cell Nuclear Antigen (PCNA) is a nuclear 
nonhistone protein that is necessary for DNA synthesis 
and is an accessory protein for DNA polymerase alpha, 
which is elevated during the G1/S phase of the cell cy-
cle. Quiescent and senescent cells have very low levels 
of PCNA mRNA (7). PCNA expression may be used 
as a marker of cell proliferation because cells remain a 
longer time in the G1/S phase when proliferating. Fur-
thermore, this protein has an essential role in nucleic 
acid metabolism as a component of the DNA replication 
and repair mechanism (8).
An increase in PCNA levels may be induced by growth 
factors or as a result of DNA damage in the absence of 
cell cycling (8,9).
PCNA is an essential factor for DNA replication and 
repair. PCNA forms a toroidal, ring-shaped structure of 
90 kDa by the symmetric association of three identical 
monomers. The ring encircles the DNA, acts as a plat-
form upon which polymerases and other proteins dock 
to perform various DNA metabolic processes, and func-
tions as a DNA polymerase-delta co-factor (10).
Various cell proliferation markers have been used in sev-
eral studies as diagnostic and prognostic tools as well as 
aids in understanding the biological behavior in many 
stages of disease. Currently, new markers are being 
added to evaluate cell proliferation. However, PCNA is 
still used as a marker of cell proliferation, and Ki-67 is 
considered the classic marker of cell proliferation and is 
in routine use by pathologists. Furthermore, several stud-
ies have been performed to evaluate cell proliferation 
using PCNA and Ki-67 in different tumors of various 
origins; compared with PCNA, Ki-67 has been shown 
to be more sensitive and specific in the various tumors 
analyzed (11-13). 
Despite the existence of these data, there are still nu-
merous studies using PCNA as the first-choice marker 
of cell proliferation (13-15). Many investigations of tu-
mor-cell proliferative activity have used PCNA and Ki-
67 to evaluate cell proliferation in oral tumors (16-18). 
The aim of this study was to determine which of the two 
markers is more useful to evaluate cell proliferation in 
the study of ameloblastic tumors.
Material and Methods
Four ameloblastic carcinomas and 161 ameloblastomas 
from the files of the Laboratory of Oral Pathology of 
the Universidad Autónoma Metropolitana Xochimilco 
(Mexico City, Mexico), a private oral pathology service 
in Mexico City and the Pathology Department of the 
Hospital “Calixto Garcia” (La Havana, Cuba) were in-
cluded. In all cases diagnosis was established according 
the criteria of the current W.H.O. Histological Classifi-
cation of Tumours (19).
The paraffin blocks were sliced into 2 µm thick sections, 
and the tissue sections were mounted on poly-lysine-
coated glass slides and air-dried overnight at room tem-
perature. After deparaffinization and rehydration, the 
tissue sections were treated with 0.1 M sodium citrate 
(pH 6.2) and Tween 20 to unravel the epitopes. Endog-
enous peroxidases were blocked with 0.9% hydrogen 
peroxide, followed by incubation with 1% bovine se-
rum albumin in PBS for 5 min to eliminate non-specific 
binding. Monoclonal antibodies were used against Ki-
67 (clone MIB-1; 1:100 dilution, Dako, Carpinteria, CA, 
USA) and PCNA (Clone PC10; dilution 1:100, Dako, 
Carpinteria, CA, USA). The sections were incubated 
with primary antibodies for 45 min; subsequently, 
the sections were incubated with a biotinylated anti-
mouse/anti-rabbit antibody and with the streptavidin/
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peroxidase complex for 30 min each (LSAB þ-labeled 
streptavidin-biotin, Dako). A 3,30-diaminobenzidine-
H2O (Dako) substrate was used to visualize the reac-
tion. Subsequently, the sections were counterstained 
with Mayer’s hematoxylin solution. For the negative 
controls, the primary antibody was replaced with PBS. 
The evaluation of Ki-67 and PCNA staining was per-
formed using selected areas that were rich in epithelial 
cells from each case of solid ameloblastomas and along 
the cyst lining and mural follicles of the unicystic vari-
ant. All of the cell counts were performed as previously 
described (20). The labeling index (number of positive 
tumor cells/total number of tumor cells expressed as a 
percentage) was calculated in every case.
Statistical analysis was performed using the chi square, 
Pearson’s or Fisher’s Exact tests, considering the ex-
pected values. The Mann–Whitney test (U-test) for dif-
ferences between the two groups or the Kruskal–Wallis 
test for differences among three or more groups was 
used to detect differences between the various types of 
lesions and the PCNA and Ki-67 indicators and Pearson 
correlation factor for analysis the correlation between 
the PCNA and Ki-67. The results were considered sig-
nificant for p≤0.05. The results were analyzed using the 
SPSS 16.0 statistical software (SPSS Professional Sta-
tistics, SPSS Inc., Chicago, IL).
Results
In the present study, 87 out of 161 cases of ameloblas-
tomaswere classified as unicystic (UA), including 46 
cases of the intraluminal variant (IUA), 26 cases of 
the mural variant (MUA) and 15 cases of the simple/
luminal variant (LUA). There were 66 cases of solid/
multicysticameloblastoma (SA), of which there were 35 
plexiform (PSA), 14 follicular (FSA), 15 acanthomatous 
(ASA) and two basal cell types (BSA). There were also 
five desmoplastic (DA) and three peripheral ameloblas-
tomas (PA). In addition, there were four ameloblastic 
carcinomas (AC).
When we analyzed the positivity for Ki-67 (using the 
labeling index), there were significant differences be-
tween the various types of ameloblastomas. The DA 
displayed a significantly lower proliferation rate (1.9%) 
compared with the rest of the central ameloblastomas 
and the ACs (p<0.05), whereas the AC demonstrated a 
significantly higher rate compared with the other benign 
ameloblastomas (48.7%) (p<0.05) (Table 1).
When analyzing cell proliferation using PCNA, we found 
significant differences only among the ameloblastic car-
cinomas (93.3%) and the DA (p<0.05), (Table 1).
When comparing the histologic subtypes, we only ob-
served some differences between the subtypes in the 
expression of both proliferation markers (Table 1).
When we compared the differences between the immu-
nopositivities for PCNA and Ki-67, it was evident that the 
percentages were higher for PCNA in all cases (Fig. 1). 
In addition, the percentages were higher than 80% in all 
lesions, whereas the immunopositivity for Ki-67 was sig-
nificantly lower; for example, AC s´ expressed the great-
est positivity for this immunomarker, but it only reached 
48.7%, while it was  93.3% when we used PCNA.
When studying the correlation between PCNA and Ki-
67, it was observed a positive and significant coefficient 
of correlation of Pearson r =.848 (p=0.000).
Histological type No.of 
cases 
PCNA (%) 
Mean ± SD
KI-67 (%) 
Mean ± SD
Unicystic (UA) 87 85.9 + 10.9 15.28 ± 11.65 
MUA 26   84.8 + 11.46  11.165 ± 10.65 
LUA 15  90.56 ± 6.45 22.99 ± 12.43 
IUA 46   85.207 ± 11.42   15.3 ± 10.98 
Solid Multicystic (SA) 66 83.73 ± 10.42   14.91 ± 11.848 
PSA 35 84.11 ± 11.03 16.13 ± 12.55 
FSA 14   82.29 ± 9.98   18.621 ± 13.46 
ASA 15   81.41 ± 9.99 8.107 ± 5.58 
BSA   2   90.8 ± 21.21   18.75 ± 0.7778 
Desmoplastic (DA)   5   80.94 ± 10.4     1.9 ± 1.24 
Peripheral (PA)   3   81.23 ± 4.56 6.86 ± 1.24 
Ameloblastic  Carcinoma (AC)   4   93.37 ± 7.76 48.7 ± 3-02 
Table 1. Percentages of expression of PCNA and Ki-67 for the histological types of ameloblas-
tomas and ameloblastic carcinomas.
IUA, intraluminal unicystic ameloblastoma; LUA, luminal unicystic ameloblastoma; MUA, 
mural unicystic ameloblastoma, FSM, folicular solid ameloblastoma; ASA, acanthomatous solid 
ameloblastoma; PSA, plexiform solid ameloblastoma.
Kruskal–Wallis test p values for Ki-67 (AC vs. DA, PA, SA, UA p < 0.05; DA vs. SA, UA p < 
0.05), PCNA (AC vs. DA; p<0.05). Pearson correlation PCNA vs Ki-67 r = .995** p<0.01 be-
tween mean of UA,SA,DA,PA and AC . Pearson correlation PCNA vs Ki-67 r=.848** p=0.000 
between mean of all histological types.  
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Discussion
The usefulness of a marker for tumor diagnosis must be 
tested for each tumor type and application. Only those 
markers that have proven to be useful in practice should 
be considered. 
The present study included a large series of ameloblas-
tic tumors, comprising 161 ameloblastomas and four 
ACs, to determine the PCNA and Ki-67 positivity of 
each ameloblastoma variant. There are some studies ad-
dressing the apparent dispute regarding which of these 
cell proliferation markers are more useful—both for 
prognostic purposes and to understand the biological 
behavior of ameloblastic tumors.
In the literature, there are some studies that have used 
both PCNA and Ki-67 as markers of cell proliferation 
in ameloblastomas (21-23). However, in our study, we 
included a larger multicentric series of ameloblastomas 
and used one simple and reproducible cell-counting 
method (20) aiming to clarify which of the two biomar-
kers is more useful for indicating the proliferation of 
these tumors. 
The term “proliferation marker” refers to specific pro-
teins or other factors whose presence in actively grow-
ing and dividing cells serve as an indicator for such 
cells, for example, PCNA and Ki-67. For this type of 
markers, two requirements have been postulated (24):
(a) The antigen should be continuously present during 
the cell cycle in all cell types, and.
(b) The transition to any non-proliferative state from 
any part of the cell cycle should be followed by a rapid 
disappearance of the antigen.
In the present study, we found significant differences 
between some types of ameloblastomas when using the 
antibody Ki-67, DA was the tumor that demonstrated the 
lowest index of proliferation; in contrast, AC displayed 
the highest index of cell proliferation in comparison with 
all types of benign ameloblastomas (p <0.05), suggesting 
a more aggressive biological behavior that is characteris-
tic of malignancy. The Ki-67 indices were similar in both 
UA (15.28%) and SA (14.9%), despite some differences 
between the various subtypes (e.g., LUA 22.99% vs. ASA 
8.10%, p<0.05). This finding could be explained by the 
fact that this variant of ameloblastoma (LUA) contains 
less stellate reticulum-like cells compared with the other 
subtypes of UA and SA; consequently, most of the cells 
that were counted corresponded to the basal or supraba-
sal layers, which are more prone to test positive. Thus, 
we conclude that the proportion of the diverse types of 
epithelial cells, as well as the different mechanisms of 
growth in UA and SA, may influence the results of the 
proliferative index (25).
In contrast, when we used the PCNA antibody, only 
one significant difference was found: the AC displayed 
a proliferation index that was relatively higher than 
one ameloblastoma (DA, p<0.05). This result clearly 
confirmed the biological behavior of the malignant 
neoplasm itself. When the various subtypes of amelob-
lastomas were compared, no significant difference was 
found among them.
It should be noted that in our study, the cell proliferation 
index, which was expressed as the percentage of positive 
cells (evaluated with the labeling index), yielded much 
higher percentages for PCNA compared with Ki-67 in 
the different variants of ameloblastic tumors; this dif-
ference was evident in all the histological subtypes of 
ameloblastomas and AC. It is important to clarify these 
findings and understand why this phenomenon occurs.
PCNA is a protein that forms a ring around a portion 
of DNA, serving to anchor the various DNA replica-
tion and repair proteins and to regulate proliferation 
throughout the cell cycle. PCNA forms a toroidal, ring-
shaped, 90-kDa structure by the symmetrical associa-
tion of three identical monomers. The ring encircles the 
DNA and acts as a platform upon which polymerases 
and other proteins dock and perform various DNA met-
abolic activities (10).
This higher PCNA positivity in the nuclei of the amel-
oblastic tumor cells can be explained by the following 
factors: PCNA is an essential molecule for the synthesis 
of DNA; although the levels of PCNA are high when the 
cell enters the cell cycle, this protein has a median life 
of at least 20 hours within the tissues (26). This finding 
could indicate that nuclei can continue to express PCNA 
even after completing the cell cycle. In addition, the 
Fig. 1. Comparative expression between Ki-
67 (left column) and PCNA (right column), 
demonstrating a higher expression of PCNA 
in the same tumoral area.
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increase of PCNA levels could be induced by growth 
factors or as a response to damaged DNA even after 
the cell is no longer active in the cell cycle. PCNA is in-
volved in the excision and replacement of abnormal nu-
cleotides and is thus also expressed in non-proliferating 
cells undergoing DNA repair (24).
Other factors that might interfere with the immunore-
activity of PCNA in stored paraffinized tissues are the 
type of fixative used and the duration and temperature 
of fixation. Furthermore, the existence of cell type-
specific differences between the effects of fixation and 
processing on the immunorecognition of Ki67 versus 
PCNA suggests that these antigens may be differential-
ly affected because they are packaged differently in the 
various types of cells (27).  
Another issue for consideration is the dilution of the an-
tibody: the lower the dilution of antibody, the higher is 
the percentage of PCNA expressed in the nucleus. 
It is important to note that the immunohistochemical 
studies for PCNA vary considerably; these differences 
may reflect the sizes of the samples, the numbers of cells 
counted per field, the cell counting techniques, and the 
statistical methods applied. 
Therefore, all of the points mentioned above could ex-
plain the increased positivity of PCNA compared with 
other markers of cellular proliferation, such as Ki-67.
Some investigations have revealed that Ki-67 is not 
subject to the influences of internal and external fac-
tors, such as PCNA; therefore, in some studies, Ki-67 
is considered to be the more specific marker of cell pro-
liferation (11,12,17). When the Ki-67 antigen was dis-
covered to be present in all proliferating cells (normal 
and tumor cells), it soon became evident thereafter that 
the presence of this protein is an excellent operational 
marker for determining the growth fraction of a given 
cell population. For this reason, antibodies against the 
Ki-67 protein are increasingly being used as diagnostic 
tools for various types of neoplasms.
The expression of the human Ki-67 protein is strictly as-
sociated with cell proliferation. During interphase, this 
antigen can be exclusively detected within the nucleus, 
whereas, in mitosis, most of the protein relocates to the 
surface of the chromosomes. The fact that the Ki-67 pro-
tein is present during all active phases of the cell cycle 
(G1, S, G2, and mitosis) but absent from resting cells (G0) 
makes it an excellent marker for determining the growth 
fraction of a given cell population (28).
In this study, when we used the proliferation cell marker 
Ki-67, the percentages obtained varied among the differ-
ent types of ameloblastomas, suggesting that Ki-67 is a 
more specific marker for the proliferation of ameloblastic 
tumor cells. This difference can be attributed to Ki-67 (a 
protein that degrades rapidly after mitosis) because it has 
a lifetime of approximately 60-90 minutes (21,29).
The prognostic value of the Ki-67 index has been esta-
blished in numerous publications. However, it is also evi-
dent that estimating the growth fraction alone is insuffi-
cient to describe tumor growth. For example, the growth 
fraction (and the Ki-67 labeling index) relates only to the 
number (or fraction) of proliferative cells but not to the 
time needed for the completion of an intermitotic cycle. 
In other words, the estimation of the growth fraction pro-
vides information only on the state but not on the rate 
of proliferation; therefore, an additional marker would be 
helpful to assess this parameter (28).
It should be emphasized that the molecular regulation of 
the cell cycle is a complex network that might include 
other factors rather than the expression of proteins, such 
as Ki-67 and PCNA. This intricate process could involve 
the modification (e.g., phosphorylation, ubiquitination), 
degradation and translocation of several key proteins.
In this paper, we clearly state that Ki-67 is a more spe-
cific proliferation marker than PCNA for ameloblastic 
tumors. It also should be recognized that a marker of cell 
proliferation can enable an understanding of how cell di-
vision works. As mentioned above, this cell division is 
influenced by several factors that are involved in tumor 
growth and tumor biology, including apoptosis, angio-
genesis, tumor invasion, and tumor histomorphology.
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